Pfizer begins phase 2b/3 trial of PF-06651600 to treat alopecia areata

Pfizer begins phase 2b/3 trial of PF-06651600 to treat alopecia areata

Source: 
Pharmaceutical Business Review
snippet: 


Pfizer has started a phase 2b/3 clinical trial of PF-06651600, an oral JAK3 inhibitor to treat patients with moderate to severe alopecia areata.